// App-Quantinova.ai

: Developments in clinical testing of cerebrospinal fluid biomarkers of Alzheimer’s disease in the UK

Researchers

Presenter

  • Ashvini Keshavan

Principal Investigators

  • Miles D Chapman

  • Melanie Hart

  • Michael P Lunn

  • Henrik Zetterberg

  • Jonathan M Schott

Medical Centers

  • University CollegeLondon, UK

  • Dementia Research Centre at UCL Queen Square Institute of Neurology

  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Sweden

  • UK Dementia Research Institute

  • Institute of Physiology and Neuroscience, University of Gothenburg

  • Neuroimmunology and CSF laboratory, National Hospital for Neurology and Neurosurgery, Queen Square

  • Department of Neuroinflammation, UCL Queen Square Institute of Neurology

  • Neuroimmunology & CSF Laboratory, Queen Square, National Hospital for Neurology and Neurosurgery

  • MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Central Nervous System (CNS)

Disease

  • Alzheimer's disease

Biomarkers

  • Amyloid beta 40

  • Amyloid beta 42

  • Cerebrospinal fluid

Drug/Treatment

  • 18F-florbetapir

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved